Dr Reddys Laboratories Ltd
₹1229.50
-9.50 (0.77%)
Wed, 28 Oct 2026, 05:33 pm
Health Technology
Pharmaceuticals: Major
24.5KDr Reddys Laboratories Ratios
| Particulars | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 74.48 | 12.02 | 22.82 | 0 | 61.71 | 25.23 | 20.98 | 17.94 | 20.32 | 26.88 | 25.94 | 36.52 | 35.29 | 24.53 | 26.55 | 43.57 | 30.39 | 17.06 | 18.43 | 16.88 |
| Price to book ratio | 5.27 | 3.06 | 2.21 | 2.33 | 5.71 | 6.03 | 5.19 | 4.12 | 4.80 | 5.34 | 4.03 | 3.52 | 2.73 | 3.28 | 3.33 | 4.32 | 3.75 | 3.33 | 3.66 | 2.86 |
| Price to sales ratio | 4.62 | 1.78 | 2 | 1.20 | 3.08 | 3.73 | 3.09 | 2.59 | 3.31 | 4.02 | 3.36 | 3.12 | 2.44 | 3 | 2.97 | 3.96 | 3.34 | 3.13 | 3.68 | 2.93 |
| Price to cash flow ratio | 94.24 | 10.06 | 20.72 | 15.65 | 11.77 | 35.84 | 19.47 | 23.33 | 22.67 | 24.08 | 12.48 | 20.72 | 20.23 | 16.54 | 17.70 | 21.09 | 25.91 | 13.30 | 22.83 | 20.60 |
| Enterprise value | 13064Cr | 12242Cr | 11221Cr | 9713Cr | 22512Cr | 29552Cr | 31333Cr | 31517Cr | 44777Cr | 59879Cr | 51257Cr | 47041Cr | 37572Cr | 47467Cr | 51406Cr | 74675Cr | 70563Cr | 72064Cr | 96466Cr | 94698Cr |
| Enterprise value to EBITDA ratio | 40.69 | 7.39 | 13.62 | 6.66 | 15.64 | 18.87 | 13.20 | 12.59 | 14.34 | 17.62 | 13.12 | 19.47 | 16.41 | 14.94 | 12.50 | 16.66 | 15.24 | 11.11 | 12.26 | 10.94 |
| Debt to equity ratio | 1.51 | 0.62 | 0.44 | 0.57 | 0.39 | 0.51 | 0.56 | 0.51 | 0.49 | 0.39 | 0.26 | 0.40 | 0.40 | 0.27 | 0.14 | 0.18 | 0.18 | 0.06 | 0.07 | 0.14 |
| Return on equity % | 7.32 | 31.85 | 10.32 | -22.86 | 9.63 | 26.36 | 27.58 | 25.77 | 26.26 | 21.95 | 16.70 | 9.54 | 7.83 | 14.10 | 13.21 | 10.51 | 12.96 | 21.38 | 21.77 | 18.42 |
Dr Reddys Laboratories Ltd Ratios
The Dr Reddys Laboratories Ltd Ratios page provides a complete fundamental analysis of Dr Reddys Laboratories Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Dr Reddys Laboratories Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Dr Reddys Laboratories Ltd (NSE: DRREDDY, BSE: 500124) is currently trading at ₹1229.50, with a market capitalization of ₹102156.38Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Dr Reddys Laboratories Ltd remains a key stock for fundamental analysis using Dr Reddys Laboratories Ltd Ratios.
Dr Reddys Laboratories Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Dr Reddys Laboratories Ltd P/E ratio currently stands at 16.88, making it one of the most tracked metrics in Dr Reddys Laboratories Ltd Ratios.
Historically, the Dr Reddys Laboratories Ltd P/E ratio has shown strong fluctuations:
- 2025: 16.88
- 2024: 18.43
- 2023: 17.06
- 2022: 30.39
- 2021: 43.57
The decline in Dr Reddys Laboratories Ltd P/E ratio suggests improving earnings relative to stock price.
Price to Book Ratio (P/B)
The Dr Reddys Laboratories Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.86.
Historical P/B trend:
- 2025: 2.86
- 2024: 3.66
- 2023: 3.33
- 2022: 3.75
Dr Reddys Laboratories Ltd shows reasonable valuation compared to its asset base.
Price to Sales Ratio (P/S)
The Dr Reddys Laboratories Ltd P/S ratio currently stands at 2.93, an important part of Dr Reddys Laboratories Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2025: 2.93
- 2024: 3.68
- 2023: 3.13
- 2022: 3.34
A stable or declining Dr Reddys Laboratories Ltd P/S ratio indicates cautious market sentiment.
Dr Reddys Laboratories Ltd Price to Cash Flow Ratio (P/CF)
The Dr Reddys Laboratories Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 20.60.
Historical Dr Reddys Laboratories Ltd Price to Cash Flow Ratio:
- 2025: 20.60
- 2024: 22.83
- 2023: 13.30
- 2022: 25.91
- 2021: 21.09
The declining Dr Reddys Laboratories Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
Dr Reddys Laboratories Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Dr Reddys Laboratories Ltd EV currently stands at ₹94698Cr, representing the total company valuation including debt.
Historical EV trend:
- 2025: 94698Cr
- 2024: 96466Cr
- 2023: 72064Cr
- 2022: 70563Cr
Dr Reddys Laboratories Ltd enterprise value consolidation suggests stable valuation.
EV/EBITDA Ratio
The Dr Reddys Laboratories Ltd EV/EBITDA ratio is currently 10.94, a key metric in Dr Reddys Laboratories Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2025: 10.94
- 2024: 12.26
- 2023: 11.11
- 2022: 15.24
Stable Dr Reddys Laboratories Ltd EV/EBITDA indicates balanced valuation.
Dr Reddys Laboratories Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Dr Reddys Laboratories Ltd D/E ratio is currently 0.14, reflecting leverage and financial stability.
Historical D/E:
- 2025: 0.14
- 2024: 0.07
- 2023: 0.06
- 2022: 0.18
Dr Reddys Laboratories Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Dr Reddys Laboratories Ltd ROE currently stands at 18.42%, showing profitability and capital efficiency.
Historical ROE:
- 2025: 18.42
- 2024: 21.77
- 2023: 21.38
- 2022: 12.96
Dr Reddys Laboratories Ltd maintains stable profitability levels.
Dr Reddys Laboratories Ltd Ratios Analysis Summary
The Dr Reddys Laboratories Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Dr Reddys Laboratories Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Dr Reddys Laboratories Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.
